

1. IDENTIFICATION OF THE MATERIAL AND SUPPLIER
1.1 Product identifier

Product name SEPTANEST WITH ADRENALINE 1:200 000 (NZ)
Synonyms SEPTANEST WITH ADRENALINE 1:200,000 • SEPTODONT SEPTANEST

1.2 Uses and uses advised against

Uses ANAESTHETIC • DENTAL APPLICATIONS • DENTAL PRODUCTS

1.3 Details of the supplier of the product

Supplier name IVOCLAR VIVADENT LTD. (NZ)
Address 12 Omega St, Rosedale, Auckland, NEW ZEALAND
Telephone + 64 9 914 9999
Fax + 64 9 914 9990
Email Customercare.nz@ivoclar.com

1.4 Emergency telephone numbers

Emergency 0800 764 766 (National Poison Centre - 24 hours / 7 days)

2. HAZARDS IDENTIFICATION
2.1 Classification of the substance or mixture

HAZARDOUS ACCORDING TO NZ ENVIRONMENTAL PROTECTION AUTHORITY CRITERIA

Physical Hazards

Not classified as a Physical Hazard

Health Hazards

Acute Toxicity: Oral: Category 4

Environmental Hazards

Not classified as an Environmental Hazard

2.2 GHS Label elements

Signal word **WARNING**

Pictograms

Hazard statements

H302 Harmful if swallowed.

Prevention statements

P264 Wash thoroughly after handling.
 P270 Do not eat, drink or smoke when using this product.

Response statements

P301 + P312 IF SWALLOWED: Call a POISON CENTRE or doctor/physician if you feel unwell.
 P330 Rinse mouth.

Storage statements

None allocated.

PRODUCT NAME SEPTANEST WITH ADRENALINE 1:200 000 (NZ)**Disposal statements**

P501 Dispose of contents/container in accordance with relevant regulations.

2.3 Other hazards

No information provided.

3. COMPOSITION/ INFORMATION ON INGREDIENTS

3.1 Substances / Mixtures

Ingredient	CAS Number	EC Number	Content
METHYL 4-METHYL-3-[[[(1-OXO-2-(PROPYLAMINO)PROPYL)AMINO]-2-THENOATE MONOHYDROCHLORIDE	23964-57-0	245-957-7	<5%
EPINEPHRINE HYDROGEN TARTRATE	51-42-3	200-097-1	<1%
NON HAZARDOUS INGREDIENTS	Not Available	Not Available	Remainder

4. FIRST AID MEASURES

4.1 Description of first aid measures

Eye	If in eyes, hold eyelids apart and flush continuously with running water. Continue flushing until advised to stop by a Poisons Information Centre, a doctor, or for at least 15 minutes.
Inhalation	If inhaled, remove from contaminated area. To protect rescuer, use an Air-line respirator or Self Contained Breathing Apparatus (SCBA). Be aware of possible explosive atmospheres. Apply artificial respiration if not breathing. Give oxygen if available.
Skin	If skin or hair contact occurs, remove contaminated clothing and flush skin and hair with running water.
Ingestion	For advice, contact the National Poisons Centre on 0800 764 766 (0800 POISON) or +643 479 7248 or a doctor (at once).
First aid facilities	Eye wash facilities and normal washroom facilities should be available.

4.2 Most important symptoms and effects, both acute and delayed

See Section 11 for more detailed information on health effects and symptoms.

4.3 Immediate medical attention and special treatment needed

Treat symptomatically.

5. FIRE FIGHTING MEASURES

5.1 Extinguishing media

Dry agent, carbon dioxide or water fog. Prevent contamination of drains and waterways.

5.2 Special hazards arising from the substance or mixture

Non flammable. May evolve toxic gases if strongly heated.

5.3 Advice for firefighters

Evacuate area and contact emergency services. Toxic gases may be evolved in a fire situation. Remain upwind and notify those downwind of hazard. Wear full protective equipment including Self Contained Breathing Apparatus (SCBA) when combating fire. Use waterfog to cool intact containers and nearby storage areas.

5.4 Hazchem code

None allocated.

6. ACCIDENTAL RELEASE MEASURES

6.1 Personal precautions, protective equipment and emergency procedures

Wear Personal Protective Equipment (PPE) as detailed in section 8 of the SDS. Clear area of all unprotected personnel. Ventilate area where possible. Contact emergency services where appropriate.

6.2 Environmental precautions

Prevent product from entering drains and waterways.

PRODUCT NAME SEPTANEST WITH ADRENALINE 1:200 000 (NZ)

6.3 Methods of cleaning up

Contain spillage, then cover / absorb spill with non-combustible absorbent material (vermiculite, sand, or similar), collect and place in suitable containers for disposal.

6.4 Reference to other sections

See Sections 8 and 13 for exposure controls and disposal.

7. HANDLING AND STORAGE

7.1 Precautions for safe handling

Before use carefully read the product label. Use of safe work practices are recommended to avoid eye or skin contact and inhalation. Observe good personal hygiene, including washing hands before eating. Prohibit eating, drinking and smoking in contaminated areas.

7.2 Conditions for safe storage, including any incompatibilities

Store in a cool, dry, well ventilated area, removed from incompatible substances, heat or ignition sources and foodstuffs. Ensure containers are adequately labelled, protected from physical damage and sealed when not in use.

7.3 Specific end uses

No information provided.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

8.1 Control parameters

Exposure standards

No exposure standards have been entered for this product.

Biological limits

Ingredient	Determinant	Sampling Time	BEI
METHYL 4-METHYL-3-[[[1-OXO-2-(PROPYLAMINO) PROPYL]AMINO]-2-THENOATE MONOHYDROCHLORIDE	Methemoglobin in blood	During or end of shift	1.5% of hemoglobin

Reference: ACGIH Biological Exposure Indices

8.2 Exposure controls

Engineering controls Avoid inhalation. Use in well ventilated areas. Where an inhalation risk exists, mechanical extraction ventilation is recommended.

PPE

Eye / Face	Wear splash-proof goggles.
Hands	Wear butyl gloves.
Body	When using large quantities or where heavy contamination is likely, wear coveralls.
Respiratory	At high vapour levels, wear Self Contained Breathing Apparatus (SCBA) or an Air-line respirator.



9. PHYSICAL AND CHEMICAL PROPERTIES

9.1 Information on basic physical and chemical properties

Appearance	COLOURLESS LIQUID
Odour	CHARACTERISTIC ODOUR
Flammability	NON FLAMMABLE
Flash point	NOT RELEVANT
Boiling point	100°C
Melting point	NOT AVAILABLE
Evaporation rate	NOT AVAILABLE
pH	5.3

9.1 Information on basic physical and chemical properties

Vapour density	NOT AVAILABLE
Relative density	NOT AVAILABLE
Solubility (water)	SOLUBLE
Vapour pressure	23 hPa @ 20°C
Upper explosion limit	NOT RELEVANT
Lower explosion limit	NOT RELEVANT
Partition coefficient	NOT AVAILABLE
Autoignition temperature	NOT AVAILABLE
Decomposition temperature	NOT AVAILABLE
Viscosity	NOT AVAILABLE
Explosive properties	NOT AVAILABLE
Oxidising properties	NOT AVAILABLE
Odour threshold	NOT AVAILABLE

10. STABILITY AND REACTIVITY

10.1 Reactivity

Carefully review all information provided in sections 10.2 to 10.6.

10.2 Chemical stability

Stable under recommended conditions of storage.

10.3 Possibility of hazardous reactions

Polymerization will not occur.

10.4 Conditions to avoid

Avoid heat, sparks, open flames and other ignition sources.

10.5 Incompatible materials

Incompatible with oxidising agents (e.g. hypochlorites) and acids (e.g. nitric acid).

10.6 Hazardous decomposition products

May evolve toxic gases if heated to decomposition.

11. TOXICOLOGICAL INFORMATION

11.1 Information on toxicological effects

Acute toxicity Harmful if swallowed.

Information available for the ingredients:

Ingredient	Oral LD50	Dermal LD50	Inhalation LC50
EPINEPHRINE HYDROGEN TARTRATE	4 mg/kg (mouse)	--	--

Skin	Contact may result in irritation, redness, pain and rash.
Eye	Contact may result in irritation, lacrimation, pain and redness.
Sensitisation	Not classified as causing skin or respiratory sensitisation.
Mutagenicity	Not classified as a mutagen.
Carcinogenicity	Not classified as a carcinogen.
Reproductive	Not classified as a reproductive toxin.
STOT - single exposure	Over exposure may result in dizziness, drowsiness, weakness, fatigue, breathing difficulties and unconsciousness.
STOT - repeated exposure	Not classified as causing organ damage from repeated exposure.
Aspiration	Not classified as causing aspiration.

12. ECOLOGICAL INFORMATION

12.1 Toxicity

Avoid release to the environment. The product should not be allowed to enter drains, water courses or the soil.

12.2 Persistence and degradability

No information provided.

12.3 Bioaccumulative potential

No information provided.

12.4 Mobility in soil

No information provided.

12.5 Other adverse effects

No additional environmental data is currently available for this product.

13. DISPOSAL CONSIDERATIONS

13.1 Waste treatment methods

Waste disposal For small amounts, absorb with sand or similar and dispose of to an approved landfill site. Contact the manufacturer/supplier for additional information (if required). Ensure that appropriate personal protective equipment is used during disposal.

Legislation Dispose of in accordance with relevant local legislation.

14. TRANSPORT INFORMATION

NOT CLASSIFIED AS A DANGEROUS GOOD ACCORDING TO LAND TRANSPORT RULE: DANGEROUS GOODS 2005; NZS 5433:2012, UN, IMDG OR IATA

	LAND TRANSPORT (NZS 5433)	SEA TRANSPORT (IMDG / IMO)	AIR TRANSPORT (IATA / ICAO)
14.1 UN Number	None allocated.	None allocated.	None allocated.
14.2 Proper Shipping Name	None allocated.	None allocated.	None allocated.
14.3 Transport hazard class	None allocated.	None allocated.	None allocated.
14.4 Packing Group	None allocated.	None allocated.	None allocated.

14.5 Environmental hazards

Not a Marine Pollutant.

14.6 Special precautions for user

Hazchem code None allocated.

EmS F-A, S-A

15. REGULATORY INFORMATION

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

Approval code HSR002558 (2020)

Group standard Dental Products (Subsidiary Hazard) Group Standard 2020

Inventory listings **AUSTRALIA: AIIIC (Australian Inventory of Industrial Chemicals)**
All components are listed on AIIIC, or are exempt.
EUROPE: EINECS (European Inventory of Existing Chemical Substances)
All components are listed on EINECS, or are exempt.

16. OTHER INFORMATION

Additional information

PRODUCT NAME SEPTANEST WITH ADRENALINE 1:200 000 (NZ)

EXPOSURE STANDARDS - TIME WEIGHTED AVERAGES: Exposure standards are established on the premise of an 8 hour work period of normal intensity, under normal climatic conditions and where a 16 hour break between shifts exists to enable the body to eliminate absorbed contaminants. In the following circumstances, exposure standards must be reduced: Strenuous work conditions; hot, humid climates; high altitude conditions; extended shifts (which increase the exposure period and shorten the period of recuperation).

WORKPLACE CONTROLS AND PRACTICES: Unless a less toxic chemical can be substituted for a hazardous substance, **ENGINEERING CONTROLS** are the most effective way of reducing exposure. The best protection is to enclose operations and/or provide local exhaust ventilation at the site of chemical release. Isolating operations can also reduce exposure. Using respirators or protective equipment is less effective than the controls mentioned above, but is sometimes necessary.

PERSONAL PROTECTIVE EQUIPMENT GUIDELINES:

The recommendation for protective equipment contained within this report is provided as a guide only. Factors such as form of product, method of application, working environment, quantity used, product concentration and the availability of engineering controls should be considered before final selection of personal protective equipment is made.

HEALTH EFFECTS FROM EXPOSURE:

It should be noted that the effects from exposure to this product will depend on several factors including: form of product; frequency and duration of use; quantity used; effectiveness of control measures; protective equipment used and method of application. Given that it is impractical to prepare a report which would encompass all possible scenarios, it is anticipated that users will assess the risks and apply control methods where appropriate.

Abbreviations

ACGIH	American Conference of Governmental Industrial Hygienists
CAS #	Chemical Abstract Service number - used to uniquely identify chemical compounds
CCID	Chemical Classification and Information Database (HSNO)
CNS	Central Nervous System
EC No.	EC No - European Community Number
EMS	Emergency Schedules (Emergency Procedures for Ships Carrying Dangerous Goods)
EPA	Environmental Protection Authority [New Zealand]
GHS	Globally Harmonized System
HSNO	Hazardous Substances and New Organisms
IARC	International Agency for Research on Cancer
LC50	Lethal Concentration, 50% / Median Lethal Concentration
LD50	Lethal Dose, 50% / Median Lethal Dose
mg/m ³	Milligrams per Cubic Metre
OEL	Occupational Exposure Limit
pH	relates to hydrogen ion concentration using a scale of 0 (high acidic) to 14 (highly alkaline).
ppm	Parts Per Million
STEL	Short-Term Exposure Limit
STOT-RE	Specific target organ toxicity (repeated exposure)
STOT-SE	Specific target organ toxicity (single exposure)
TLV	Threshold Limit Value
TWA	Time Weighted Average

Report status

This document has been compiled by RMT on behalf of the manufacturer, importer or supplier of the product and serves as their Safety Data Sheet ('SDS').

It is based on information concerning the product which has been provided to RMT by the manufacturer, importer or supplier or obtained from third party sources and is believed to represent the current state of knowledge as to the appropriate safety and handling precautions for the product at the time of issue. Further clarification regarding any aspect of the product should be obtained directly from the manufacturer, importer or supplier.

While RMT has taken all due care to include accurate and up-to-date information in this SDS, it does not provide any warranty as to accuracy or completeness. As far as lawfully possible, RMT accepts no liability for any loss, injury or damage (including consequential loss) which may be suffered or incurred by any person as a consequence of their reliance on the information contained in this SDS.

PRODUCT NAME SEPTANEST WITH ADRENALINE 1:200 000 (NZ)

Prepared by

Risk Management Technologies
5 Ventnor Ave, West Perth
Western Australia 6005
Phone: +61 8 9322 1711
Fax: +61 8 9322 1794
Email: info@rmt.com.au
Web: www.rmtglobal.com

[End of SDS]